Argenx's stock surged 16.66% following positive Phase III ALKIVIA trial results for its autoimmune drug Vyvgart Hytrulo, showing significant efficacy in treating autoimmune myositis. Analyst firm William Blair reaffirmed an 'Outperform' rating, reflecting strong confidence in the company's future. The successful trial marks a major milestone for Vyvgart DM, targeting dermatomyositis, and boosts investor optimism with Argenx's market value reaching about $61.76 billion. This development highlights Argenx's growing role in autoimmune disease treatment innovation.
Chery unveiled its Globalisation 3.0 strategy at the 2026 International User Summit, aiming to transform from a traditional automaker into a high-tech integrated ecosystem by 2035. The strategy emphasizes AI adoption, green technologies, and local ma...
Unfair Links, founded by Rollo Unden and Oliver Fish, has launched a beta service providing local backlinks that are matched to a business's Google Business Profile, country, language, and page topic. Unlike generic backlinks, these links come from r...
Tango, a global live-streaming platform, has donated tens of thousands of dollars to support FRIDA Ukraine's mobile cancer screening program. This initiative brings essential cancer detection and preventive healthcare services directly to underserved...
California's upcoming AI safety mandate, effective May 15, 2027, is creating tension with federal military cybersecurity rules under the Defense Federal Acquisition Regulation Supplement (DFARS). Veteran-led engineering groups have developed advanced...
The Rosen Law Firm is investigating potential securities claims for J.B. Hunt Transport Services shareholders following a sharp 10% stock drop after the company warned of lower third-quarter earnings due to increased costs. Investors who bought J.B. ...
